BUSINESS● LOWAug 25 · Aug 25, 2026, 9:01 PM
Spyre drops on disappointing phase 2 data for rheumatoid arthritis asset
Seeking Alpha Tech
Spyre's stock has declined following the release of disappointing Phase 2 clinical trial data for its rheumatoid arthritis treatment. This indicates a setback in the company's drug development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS9m agoHow a $5 billion ‘Gas Ring’ could strengthen Central Asia’s energy securityEuroNews [en]BUSINESS14m agoLCFE bets on Commodities Exchange for transparent petroleum pricing, market efficiencyVanguard Nigeria